Double Germline Mutations in the RET Proto-oncogene in MEN 2A and MEN 2B Kindreds
Overview
Authors
Affiliations
Medullary thyroid carcinoma (MTC) is a rare form of thyroid cancer representing about 10% of all thyroid malignancies. It occurs mostly as a sporadic tumor or in association with autosomal dominant inherited cancer syndromes--multiple endocrine neoplasia (MEN) types 2A and 2B and familial MTC. Germline mutations in exons 8, 10, 11, 13, 14, 15 and 16 of the RET proto-oncogene are found in most of the familial cases. There are only a few published data reporting multiple germline mutations in the RET proto-oncogene. We have detected double germline mutations in 2 different exons on the same RET allele in two MEN 2 families. In the MEN 2A family, double germline mutation in exons 10 (Cys620Phe) and 13 (Tyr791Phe) was detected. In the MEN 2B family, beside the classical germline mutation in exon 16 (Met918Thr) a second germline mutation in exon 13 (Tyr791Phe) was found. This study revealed that MEN 2 syndromes can also be caused by double germline mutations in the RET proto-oncogene and these families can be added to small worldwide cohort of families with multiple germline mutations.
Current status of the prognostic molecular markers in medullary thyroid carcinoma.
Oczko-Wojciechowska M, Czarniecka A, Gawlik T, Jarzab B, Krajewska J Endocr Connect. 2020; 9(12):R251-R263.
PMID: 33112827 PMC: 7774764. DOI: 10.1530/EC-20-0374.
Li S, Ding Y, Si Y, Ye M, Xu C, Qi X Front Endocrinol (Lausanne). 2020; 11:543246.
PMID: 33071967 PMC: 7531599. DOI: 10.3389/fendo.2020.543246.
Revised American Thyroid Association guidelines for the management of medullary thyroid carcinoma.
Wells Jr S, Asa S, Dralle H, Elisei R, Evans D, Gagel R Thyroid. 2015; 25(6):567-610.
PMID: 25810047 PMC: 4490627. DOI: 10.1089/thy.2014.0335.
Kihara M, Miyauchi A, Yoshida H, Yamada O, Masuoka H, Yabuta T Eur Thyroid J. 2015; 3(4):272-7.
PMID: 25759805 PMC: 4311302. DOI: 10.1159/000369134.
Valente F, Dias da Silva M, Camacho C, Kunii I, Bastos A, da Fonseca C J Endocrinol Invest. 2013; 36(11):975-81.
PMID: 23723040 DOI: 10.3275/8997.